Recent rapid biotechnological breakthroughs have led to the identification of complex and
unique molecular features that drive malignancies. Precision medicine has exploited next …

Although more than a decade has passed since the approval of immune checkpoint
inhibitors (ICIs) for the treatment of melanoma and non-small-cell lung, breast and …

Background Pembrolizumab has shown improved progression-free survival versus
chemotherapy in patients with newly diagnosed microsatellite instability-high or mismatch …

Immune checkpoint inhibitor (ICI) therapy can induce complete responses in mismatch
repair-deficient and microsatellite instability-high (d-MMR/MSI-H) colorectal cancers (CRCs) …

Colorectal cancer (CRC) is the fourth most frequently diagnosed cancer and the second
leading cause of cancer death in the United States. Management of disseminated metastatic …

Background Pembrolizumab demonstrated durable antitumor activity in 233 patients with
previously treated advanced microsatellite instability high (MSI-H) or mismatch repair …

PURPOSE Nivolumab received US Food and Drug Administration approval as a single
agent or in combination with ipilimumab in patients with microsatellite instability …

In the era of targeted therapy based on genomic alterations, the treatment strategy for
metastatic colorectal cancer (mCRC) has been changing. Before systemic treatment …

Microsatellite unstable (MSI) colorectal cancers (CRCs) are due to DNA mismatch repair
(MMR) deficiency and occurs in15% of non-metastatic diseases and 5% in the metastatic …

The mutational landscape of colorectal cancer (CRC) does not enable predictions to be
made about the survival of patients or their response to therapy. Instead, studying the …